• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Revista Cubana de Hematología, Inmunología y Hemoterapia >High-dose dexamethasone in chronic primary immune thrombocytopenia
【24h】

High-dose dexamethasone in chronic primary immune thrombocytopenia

机译：大剂量地塞米松治疗慢性原发性免疫性血小板减少症

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A prospective, analytical and applied study was conducted to determine the effectiveness of treatment with high-dose dexamethasone in patients with chronic primary immune thrombocytopenia, who were assisted at the Hemostasis service of the Institute of Hematology and Immunology from April 2008 to April 2011. 30 patients, 18 females and 12 males with an average age of 37 years were studied. Favorable response was achieved in 17 patients (68.0%), out of them, 14 had complete and 3 had partial remission respectively. No response was obtained in eight patients. A significant increase in platelet count was observed during the whole therapy. Referrals are obtained early, from the first to the third cycle, and late responses were not observed. Most patients who responded to previous treatment with prednisone had a favorable response to dexamethasone. In general, adverse events were mild and the most frequent were myalgia, edema, and arthralgias. Three patients required stopping the treatment because of side effects and nine maintained remission during the follow-up period. High-dose dexamethasone is an effective and safe alternative treatment in patients with chronic primary immune thrombocytopenia.
机译：进行了一项前瞻性，分析和应用研究，以确定大剂量地塞米松对慢性原发性免疫性血小板减少症患者的治疗效果，这些患者于2008年4月至2011年4月在血液学和免疫学研究所的止血服务中得到协助。30研究人员对平均年龄为37岁的18例女性和12例男性进行了研究。 17例患者（68.0％）获得了良好的缓解，其中14例完全缓解，3例部分缓解。八名患者没有反应。在整个治疗过程中，血小板计数显着增加。从第一个周期到第三个周期，很早就获得了推荐，没有观察到较晚的响应。对以前用泼尼松治疗有反应的大多数患者对地塞米松有良好的反应。通常，不良事件较轻，最常见的是肌痛，浮肿和关节痛。由于副作用，三名患者需要停止治疗，九名患者在随访期间保持缓解。大剂量地塞米松是慢性原发性免疫性血小板减少症患者的一种安全有效的替代疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号